Four years after purchasing Esperion Therapeutics Inc., a company focused on the discovery and development of compounds for cardiovascular and metabolic disease, Pfizer Inc. is selling the Ann Arbor, Mich.-based firm to an entity funded by a group of investors. (BioWorld Today)